Catalyst Pharmaceuticals, Inc. (CPRX)
 NASDAQ: CPRX · Real-Time Price · USD
 20.97
 -0.04 (-0.19%)
  At close: Oct 30, 2025, 4:00 PM EDT
20.85
 -0.12 (-0.57%)
  After-hours: Oct 30, 2025, 7:13 PM EDT
Catalyst Pharmaceuticals Revenue
Catalyst Pharmaceuticals had revenue of $146.56M in the quarter ending June 30, 2025, with 19.44% growth. This brings the company's revenue in the last twelve months to $558.50M, up 28.55% year-over-year. In the year 2024, Catalyst Pharmaceuticals had annual revenue of $491.73M with 23.49% growth.
Revenue (ttm) 
 $558.50M
Revenue Growth 
 +28.55%
P/S Ratio 
 4.54
Revenue / Employee 
 $3,085,630
Employees 
 181
Market Cap 
2.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 491.73M | 93.53M | 23.49% | 
| Dec 31, 2023 | 398.20M | 184.00M | 85.90% | 
| Dec 31, 2022 | 214.20M | 73.37M | 52.10% | 
| Dec 31, 2021 | 140.83M | 21.76M | 18.27% | 
| Dec 31, 2020 | 119.07M | 16.77M | 16.39% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
CPRX News
- 8 days ago - Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 21 days ago - Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewsWire
- 4 weeks ago - Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals - GlobeNewsWire
- 3 months ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update - GlobeNewsWire